Nymox Pharmaceutical annual shares outstanding
2016
2017
2018
2019
2020
2021
2022
2023
2024
Nymox Pharmaceutical Shares Outstanding History (NYMXF)
Nymox Pharmaceutical reported 94.5M shares outstanding at the end of fiscal 2024.
View full Nymox Pharmaceutical company overviewNymox Pharmaceutical annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 94.5M | 1.0M | +1.07% |
| 2023 | 2023-12-31 | 93.5M | 3.0M | +3.34% |
| 2022 | 2022-12-31 | 90.5M | 5.0M | +5.81% |
| 2021 | 2021-12-31 | 85.5M | 7.6M | +9.73% |
| 2020 | 2020-12-31 | 78.0M | 6.7M | +9.47% |
| 2019 | 2019-12-31 | 71.2M | 6.5M | +10.12% |
| 2018 | 2018-12-31 | 64.7M | 8.3M | +14.72% |
| 2017 | 2017-12-31 | 56.4M | 7.3M | +14.79% |
| 2016 | 2016-12-31 | 49.1M | — | — |
Nymox Pharmaceutical quarterly shares outstanding
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q3.24
Q4.24
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | 94.5M | 1.0M | +1.07% |
| Q3 2024 | 2024-09-30 | 93.5M | 275,000 | +0.29% |
| Q4 2023 | 2023-12-31 | 93.5M | 3.0M | +3.34% |
| Q3 2023 | 2023-09-30 | 93.3M | 2.0M | +2.19% |
| Q2 2023 | 2023-06-30 | 91.3M | 0 | 0.00% |
| Q1 2023 | 2023-03-31 | 90.5M | 235,000 | +0.26% |
| Q4 2022 | 2022-12-31 | 90.5M | 5.0M | +5.81% |
| Q3 2022 | 2022-09-30 | 91.3M | — | — |
| Q2 2022 | 2022-06-30 | 91.3M | — | — |
| Q1 2022 | 2022-03-31 | 90.3M | — | — |
| Q4 2021 | 2021-12-31 | 85.5M | 7.6M | +9.73% |
| Q4 2020 | 2020-12-31 | 78.0M | 6.7M | +9.47% |
| Q3 2020 | 2020-09-30 | 77.2M | 6.7M | +9.57% |
| Q2 2020 | 2020-06-30 | 72.7M | 3.0M | +4.30% |
| Q1 2020 | 2020-03-31 | 71.7M | 3.8M | +5.58% |
| Q4 2019 | 2019-12-31 | 71.2M | 6.5M | +10.12% |
| Q3 2019 | 2019-09-30 | 70.5M | 8.2M | +13.19% |
| Q2 2019 | 2019-06-30 | 69.7M | 9.0M | +14.78% |
| Q1 2019 | 2019-03-31 | 67.9M | 10.1M | +17.43% |
| Q4 2018 | 2018-12-31 | 64.7M | 8.3M | +14.72% |
| Q3 2018 | 2018-09-30 | 62.3M | — | — |
| Q2 2018 | 2018-06-30 | 60.7M | — | — |
| Q1 2018 | 2018-03-31 | 57.8M | — | — |
| Q4 2017 | 2017-12-31 | 56.4M | — | — |
Nymox Pharmaceutical shares outstanding trends
Over the last five fiscal years, Nymox Pharmaceutical's shares outstanding moved from 71.2M to 94.5M, a change of 23.3M. The latest reported quarter, Q4 2024, shows 94.5M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nymox Pharmaceutical source filings ↗